A policy that would let compounding pharmacies make some popular peptides is now sitting with the White House for review — the clearest sign yet that the FDA’s long standoff over peptide access is starting to move. The same week, a new investigation gathered firsthand accounts from people who say a widely used recovery peptide left them with lingering symptoms. Together, the two stories capture the tension regulators are trying to resolve: demand for peptide access is moving faster than the safety evidence behind it.
A Peptide Compounding Policy Lands at the White House
On October 14, 2026, HHS submitted a filing titled the “Interim Access Policy for Compounding Using Certain Peptides” to the White House Office of Management and Budget, which reviews rules with significant economic impact. The filing discloses no specifics, but people familiar with the plan told the Associated Press it would let licensed compounding pharmacies temporarily make some popular peptides without being targeted for enforcement — an approach called “enforcement discretion.” That’s a different, faster mechanism than formally adding a peptide to the FDA’s approved compounding list, which requires years of rulemaking and public comment.
The plan follows a July 2026 vote by the FDA’s Pharmacy Compounding Advisory Committee (PCAC), which recommended six peptides — BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax — for that list, even as FDA’s own staff scientists said none had been studied enough to establish safety and effectiveness. Analysts estimate the addressable peptide market at $2–3 billion, and telehealth companies including Hims & Hers and Noom have said they’ll offer peptides if federal access eases.
Why It Matters
Enforcement discretion is faster than formal rulemaking, but it’s also a lower bar: it doesn’t require the FDA to find a peptide safe or effective, only that the agency won’t currently pursue pharmacies for making it. A peptide the FDA is temporarily declining to act against isn’t the same as one reviewed against controlled trial data — a gap the next story tests directly.
A New Investigation Surfaces Patient Reports of Harm
One day earlier, on October 13, 2026, KFF Health News — also published by The Washington Post — ran an investigation gathering firsthand accounts from people who say BPC-157, one of the six peptides recommended for the compounding list, left them with lasting symptoms. One man described months of anxiety along with eye and muscle twitching after buying it online from a seller that labeled it “for laboratory research only.” Another described two months of migraines and facial numbness after combining it with a second peptide. A Michigan school employee who used it alongside a separate weight-loss peptide said she stopped after experiencing pain.
The FDA’s own adverse-event database includes unverified reports consistent with those accounts, including a hospitalization associated with BPC-157 use, and a 2020 animal study found signs of liver toxicity in rats and dogs given the peptide. Researchers quoted in the piece — including a liver disease specialist who voted against the July PCAC recommendation, and physician-researcher Eric Topol — noted that slow-developing harms like liver damage can take years to surface, and that voluntary adverse-event reports can’t by themselves establish that a peptide caused a given symptom. An HHS spokesperson maintained that the FDA, not advocacy or politics, will make the final listing decision.
Why It Matters
BPC-157 sits at the center of the policy now under White House review. The investigation doesn’t prove the peptide caused the symptoms described, and none of its evidence is independently verified. But it’s a pointed reminder that “recommended by an advisory panel” and “reviewed against controlled trial data” are two different things — and the policy moving through OMB would let pharmacies compound this peptide before that gap closes.
Where the Compounding Review Stands
The PCAC’s July 2026 recommendation of six peptides for the 503A list — BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax — has not been finalized through formal rulemaking, and the second, larger PCAC review of additional peptides, reportedly including GHK-Cu, LL-37, Dihexa, Melanotan II, and PEG-MGF, is expected before February 2027. The interim access policy submitted to OMB would not wait for that rulemaking, but it also would not apply to research-use-only products, supplements, or peptides compounded outside licensed 503A pharmacies. Separately, the Seventh Circuit has not ruled on retatrutide’s drug-versus-biologic classification since hearing oral argument on September 24 — a question we covered in detail when Lilly’s first phase 3 data published — and the EVEXIAS Life Sciences lawsuit challenging the FDA’s “Category 2” peptide restrictions also remains unresolved.
How to Tell a Licensed Compounding Pharmacy From a Gray-Market Seller
Enforcement discretion, if it takes effect, would apply to a specific category: pharmacies licensed as 503A compounders making a defined set of peptides under a valid prescription. It would not legalize research-only vials sold online, supplement-shelf products, or injectables sold with no prescription.
- Check for a prescription requirement. A licensed 503A pharmacy fills a compounded prescription a physician writes after an individualized evaluation. A seller shipping with no prescription or medical oversight sits outside that system regardless of the label.
- Look past “research use only.” The FDA has repeatedly rejected that label as a shield when a product is clearly marketed for human use, most recently in its August 2026 warning letters to four peptide vendors.
- Ask where it’s licensed. A 503A pharmacy holds a state pharmacy license subject to board inspection. No listed license, no verifiable U.S. address, or sourcing from unregulated overseas suppliers all signal meaningfully higher contamination risk.
- Separate “recommended” from “approved.” A committee vote is a non-binding recommendation. Approval requires the review process — or, for now, the enforcement-discretion policy — the agency is still working through.
What This Means for Patients
- Talk to a licensed physician before starting any peptide or hormone therapy, so someone familiar with your full health history — not a product page — weighs the risks.
- Use only licensed U.S. pharmacies for anything compounded, and confirm that license with the relevant state board of pharmacy if you have any doubt.
- Avoid products labeled “research use only” or sold with no prescription. That label doesn’t change the legal status or safety profile of what’s inside the vial.
FAQ
What did HHS send to the White House this week?
On October 14, 2026, HHS submitted an “Interim Access Policy for Compounding Using Certain Peptides” to OMB for review. The filing discloses no specifics, but people familiar with it say it would use enforcement discretion to let licensed pharmacies temporarily compound certain peptides.
Does this mean peptides like BPC-157 are now FDA-approved?
No. Enforcement discretion means the FDA is choosing not to currently pursue enforcement against certain compounding activity — it isn’t an approval and doesn’t require a finding that a peptide is safe or effective. No peptide has been added to the FDA’s approved 503A bulk compounding list.
What is “enforcement discretion,” and how is it different from formal rulemaking?
Enforcement discretion assures pharmacies they won’t be targeted for making a specific peptide, without changing the underlying rule. Formally adding a peptide to the approved list requires years of rulemaking with public comment; the policy under White House review reportedly uses the faster route instead.
What did the new investigation into patient harm report?
KFF Health News and The Washington Post published firsthand accounts of people who said BPC-157 left them with symptoms including months of anxiety, migraines, facial numbness, and eye or muscle twitching. The reports aren’t independently verified and don’t establish the peptide caused the symptoms, but researchers quoted in the piece said some risks, like liver damage, can take years to surface.
Has the Seventh Circuit ruled on retatrutide’s legal classification?
No. The court heard oral argument on September 24, 2026, and hasn’t issued a decision. Appellate rulings of this kind typically take weeks to months.
This article is for informational purposes only and does not constitute medical advice. Prestigious Health does not sell, offer or prescribe products that lack FDA approval or a lawful compounding pathway.
Sources
- STAT News — Trump administration advances plan for peptide drugs favored by RFK Jr. (October 15, 2026)
- Becker’s Hospital Review — HHS sends peptide compounding plan to White House: 5 things to know
- Holland & Knight — Peptides at a Crossroads: What Wellness Providers Need to Know About HHS and FDA Actions (October 2026)
- KFF Health News — People Say These Peptides Hurt Them. Their Stories Are Muffled in MAHA’s Push for Medical Freedom (October 13, 2026)
- The Washington Times — HHS proposes letting pharmacies make peptides (October 16, 2026)